There are indications that the cytokine interleukin (IL)-10 has a regulatory role in EpsteinBarr virus (EBV)-induced infections. Because the human IL-10 gene demonstrates polymorphism resulting in interindividual differences in cytokine production, the frequencies of the alleles defined by the base exchange polymorphism at the position Ϫ1082 (allele , allele 1 ϭ G ) were analyzed in EBV-seronegative adults, seropositive adults, and in patients hos-2 ϭ A pitalized because of a severe EBV infection. The frequencies of allele 1 were 0.80, 0.46, and 0.29, respectively. Because this allele is associated with a high IL-10-producing capability, these data suggest that high IL-10 levels protect against EBV infection and, conversely, that low IL-10-producing capability makes individuals more susceptible to a severe EBV infection.
also been implicated as a causative agent in Burkitt's lymphoma, nasopharyngeal carcinoma, and Hodgkin's disease [1] .
EBV is an exclusively human pathogen that is transmitted by salivary contact. During acute infection, EBV causes lytic infection in epithelial cells of the nasopharynx and salivary glands, which is followed by latent infection mainly in B cells [1] . During acute infection, the infected B cells proliferate extensively and are controlled first by interferon (IFN)-g and natural killer (NK) cells and later by virus-specific cytotoxic T cells and antibody response. Symptomatic infection, acute IM, is thought to result from the host's reaction against the virus [1] . Latently infected B cells express continuously several viral proteins that are recognized by the host's cytotoxic T cells. Therefore, balance between the virus residing in B cells and the host's immune response is essential for the maintenance of viral latency.
Since the cell-mediated immune response is essential for the control of the acute infection and viral latency and also promotes symptomatic disease, cytokines are believed to play an important role in EBV infection. Several cytokines are present in EBV infection and its more malignant disease manifestations [1] . However, the clinical relevance of these findings is unclear because the short half-life and numerous interactions of the cytokines complicate the clinical picture. The genetic polymorphism of cytokines and their connections to clinical disease manifestations probably are more relevant. We previously showed that the frequencies of the IL-1b alleles and their association with the interleukin (IL)-1-RA locus alleles differ in EBV-seronegative and -seropositive adults [2] .
EBV carries a genetic element, BCRF1, which is highly homologous to the human IL-10 gene and shares most of its functions [3] . EBV probably captured this gene during evolution to its own advantage, but the pathophysiologic role of this viral IL-10 is still unknown. Several polymorphic sites of the IL-10 gene have been identified. Three polymorphic sites are located in the promoter region of the gene. The base exchange polymorphism at position Ϫ1082 analyzed in this study has been connected to differential IL-10 expression in vitro [4] . In this study, we analyzed the genetic polymorphism of IL-10 in three groups: persons who had experienced an acute EBV infection with prolonged fever, adults with probable history of asymptomatic or mildly symptomatic infection, and seronegative adults.
Patients and Methods
Subjects and methods. The study was carried out at Tampere University Hospital and the University of Tampere Medical school. Blood samples were obtained from three groups: (1) Patients who had experienced an aggressive, acute EBV infection ( ); (2) n ϭ 36 healthy EBV-seropositive blood donors ( ); (3) and healthy n ϭ 52 EBV-seronegative blood donors ( ). Subjects in group 1 were n ϭ 20 selected retrospectively on the basis of hospital records. In all, 220 adults and children were hospitalized between 1987 and 1997 because of EBV infection. We used fever of 17 days as selection criteria for group 1. Of the 72 patients who had experienced prolonged fever, 36 agreed to participate. None of the patients in group 1 had any immunologic condition, such as malignancy or immunodeficiency, that might affect the clinical picture of their acute EBV infection. The diagnosis of acute EBV infection was based on positive IgM serology measured by EIA and symptoms compatible with acute EBV infection. Samples from the blood donors were obtained from the Finnish Red Cross Blood Transfusion Centre, Tampere. IgG anti-EBV antibodies were measured from the plasma samples by EIA (Enzygnost anti-EBV/IgG; Behringwerke, Marburg, Germany). Twenty of the 400 blood donors screened were seronegative for EBV and were included in the study. Of the 380 EBV-seropositive blood donors, 52 were randomly chosen for gene polymorphism analysis.
Analysis of IL-10 gene promoter polymorphism. Genomic DNA was isolated by the salting out method [5] . Polymerase chain reaction (PCR) for IL-10 gene promoter region (between Ϫ528 and Ϫ1115) was done using oligonucleotides 5 -ATCCAAGACAA-CACTACTAA-3 (upstream) and 5 -TAAATATCCTCAAAG-TTCC-3 (downstream) as primers. Samples were amplified in a 50-mL total volume using a master mix solution containing 1.25 U of DNA polymerase (Dynazyme II; Finnzymes, Espoo, Finland), 5 mL of optimized 10ϫ buffer for Dynazyme II (Finnzymes), 10 mM dNTP mix, and 20 pmol of each primer. Conditions used were a denaturing step of 95ЊC for 3 min, 30 cycles at 95ЊC for 30 s, 56ЊC for 30 s, 72ЊC for 1 min, and a final incubation at 72ЊC for 3 min. Samples were purified with a PCR purification kit (QIAquick; Qiagen, Hilden, Germany). Polymorphism of the IL-10 gene promoter at Ϫ1082 was established by cycle sequencing using primer 5 -ACACCATCTCCAGCACATAG-3 , a cycle sequencing ready reaction kit, and a genetic analyzer (ABI PRISM kit and PRISM 310, respectively; Perkin-Elmer, Foster City, CA).
Statistics. Statistical analysis was done by x 2 test.
Results
The IL-10 polymorphism (G to A exchange at position Ϫ1082) was analyzed in 52 seropositive and 20 seronegative blood samples and for the 36 patients who had experienced an EBV infection requiring hospitalization. A clear difference was observed: EBV-seronegative blood donors were more likely to carry the allele 1 (G) than were seropositive blood donors or persons with a severe EBV infection (0.80 vs. 0.46, ; P ! .001 0.80 vs. 0.29, ). The difference between the EBV-P ! .001 seropositive group and the disease group was also statistically significant ( , x 2 test; table 1). P ! .02 Thirty-six persons who had experienced an acute EBV infection with fever for 17 days participated in the study. The clinical characteristics of these persons are shown in table 2. Eight of the 36 had complications during EBV infection, and 7 of the 8 required antibiotic treatment for identified bacterial infection: 3 with maxillary sinusitis were diagnosed because of pressure symptoms by needle puncture, 2 needed emergency tonsillectomy/drainage because of tonsillar abscess, and 2 were treated in the intensive care unit (ICU) because of lifethreatening complications.
When the 8 patients with complications were compared with the 28 patients with prolonged fever but without major complications, those with complications were less likely to carry the allele 1 than were the other 28 patients (0.13 vs. 0.34). However, this difference did not reach statistical significance. Differential expression of IL-10 has been implicated in sev- eral autoimmune diseases, because of its effect on B cell proliferation and cell-mediated immunity, and also in some infectious conditions. Abnormally high IL-10 levels have been shown in patients with systemic lupus erythematosus (SLE) and high production has been connected to disease activity [7] . SLE is characterized by impaired T cell responses and B cell dysregulation, leading to hyperimmunoglobulinemia and autoantibody formation. The severity of asthma and certain subtypes of rheumatoid arthritis have also been connected to genotypes of IL-10 [8, 9] . In meningococcal disease, the risk for fatal outcome is increased in families with high IL-10 production [10] . In EBV infection, abnormally high circulating levels of IL-10 are found in persons with both acute and chronic infections [1] . In the present study, the allele 1 of IL-10 (position Ϫ1082) was more common in seronegative blood donors and in persons with mildly symptomatic or asymptomatic disease than in patients with EBV infection requiring hospitalization. Turner et al. [4] have connected allele 1 with increased in vitro production of IL-10. Because IL-10 is an antiinflammatory cytokine, it is not surprising that persons with the capacity to produce low amounts of IL-10 have an aggressive, symptomatic disease. In this study, 8 patients had EBV infections with bacterial complications or required ICU treatment because of severe EBV infection. In these persons, the frequency of allele 1 of the antiinflammatory cytokine IL-10 was decreased even further, although not statistically so, compared with persons with active infection without complications, moving the balance to the direction of increased production of proinflammatory cytokines.
How the increased production of IL-10 connected to allele 1 protects against EBV infection is unclear. Huber et al. [11] suggested that EBV-induced stimulation of T cells is required for establishing a persistent infection in B cells. Therefore, if this stimulation is not sufficient because of high IL-10 production, it could interfere with the T cell-B cell interaction and prevent persistent infection. According to this hypothesis, increased production of antiinflammatory cytokines may protect against persistent EBV infection. However, even though IL-10 is considered immunosuppressive, some data support the opposite effect in EBV infection. Infection of immunodeficient mice with IL-10-expressing vaccinia virus has been shown to increase NK cell function compared to that of IL-10-deficient virus [12] . IL-10 also enhances T cell cytotoxicity against EBVinfected cells in vitro and prevents apoptosis of T cells from persons with IM [13, 14] . The increased production of IL-10 by the host could activate the NK and T cell system to the extent that latent EBV infection would be prevented. The explanation for the persistent seronegativity of some adults would be eradication of the virus at the beginning of infection.
The role of vIL-10 in EBV infection is also unclear. Swaminathan et al. [15] showed that, when BCRF1 gene encoding for vIL-10 was mutated, it had no effect on latent infection, B lymphocyte proliferation, or viral replication. However, mutant viruses lacking vIL-10 production stimulated higher amounts of IFN-g than did wild type viruses. Production of vIL-10 may therefore have some importance in establishing a latent infection.
